XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference
May 15 2017 - 4:05PM
XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and
development of therapeutic antibodies, announced today that Jim
Neal, Chief Executive Officer, will present the Company’s new
strategic initiatives and value drivers at the UBS Global
Healthcare Conference on Monday, May 22, 2017, at 8:30 a.m. ET. The
conference is being held at the Grand Hyatt New York hotel.
A live audio webcast of the presentation can be accessed in the
Investors and Media section of XOMA's website
at http://investors.xoma.com/events.cfm. An archived version
of the webcast will be available via replay for 90 days following
the presentation.
About XOMA CorporationXOMA has an extensive
portfolio of products, programs, and technologies that are the
subject of licenses the Company has in place with other biotech and
pharmaceutical companies. Many of these licenses are the result of
the Company’s pioneering efforts in the discovery and development
of antibody therapeutics. There are more than 20 such programs that
are fully funded by partners and could produce milestone payments
and royalty payments in the future. In order to maximize its value
in a licensing transaction, XOMA continues to invest in X358, an
allosteric monoclonal antibody that reduces insulin receptor
activity, as the antibody could have a major impact on the
treatment of hyperinsulinism. For more information, visit
www.xoma.com.
CONTACTS:
Investor contact:
Luke Heagle
Pure Communications
+1 910-726-1372
lheagle@purecommunications.com
Media contact:
Colin Sanford
Pure Communications
+1 415-946-1094
csanford@purecommunications.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024